Menopur (Menotrophin)

Menotropin contains both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) analogues. After injection, the FSH component activates granulosa cell receptors, promoting estradiol production and follicle growth, while the LH component stimulates theca cells and mature granulosa cells to convert androgens to estrogen and trigger ovulation. The combined activity reproduces the natural pituitary surge that drives follicular maturation and ovulation.

The dose of Menopur is individualized and determined by the prescribing clinician based on the patient’s ovarian reserve, treatment protocol, and response to monitoring. Dosing may be started at a low unit amount and adjusted according to ultrasound and hormone measurements. Exact regimens should only be set by a qualified healthcare professional.

Menopur is intended for use before conception to facilitate ovulation and should not be continued during an established pregnancy. Its safety in pregnancy has not been established, and it is generally avoided once pregnancy is confirmed. Limited data exist for use during breastfeeding; therefore, the medication is usually discontinued during lactation unless specifically advised by a specialist.

To order Menopur, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain handling if required) and any necessary import documentation.

The primary alternatives to Menopur are recombinant FSH (rFSH) and recombinant LH (rLH) preparations, which provide isolated hormone activity. Menopur offers a fixed 1:1 FSH to LH ratio in a single formulation, which can simplify dosing and reduce injection burden. Recombinant products allow separate titration of each hormone but may be more expensive. Clinical choice depends on patient response, protocol design and cost considerations.

Menopur should be stored at 2‑8 °C (refrigerated) in its original packaging, protected from light. Do not freeze or shake the vial. Before use, reconstitute the powder with the supplied diluent under aseptic conditions, and use the solution within the time frame indicated in the product label. Any unused solution should be discarded according to local regulations.

Menopur is administered by subcutaneous or intramuscular injection, typically in the abdominal wall, thigh, or buttock. The reconstituted solution is drawn into a sterile syringe and injected according to the dosing schedule prescribed by the fertility specialist. Injection technique, site rotation and proper aseptic practice are essential to minimise discomfort and infection risk.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, abdominal distension, ascites, respiratory compromise, and thromboembolic events. Early recognition of symptoms such as sudden abdominal pain, shortness of breath, or significant swelling is critical. Prompt medical evaluation is required to manage these potentially life‑threatening complications.

Menopur is contraindicated in women with active ovarian cysts, uncontrolled thyroid disease, estrogen‑dependent neoplasms, severe ovarian hyperstimulation syndrome, or known hypersensitivity to menotropin or any excipients. It should also be avoided in patients with uncontrolled cardiovascular disease or severe liver dysfunction. Men should not use Menopur unless specifically indicated for hypogonadotropic hypogonadism under specialist supervision.